Tumour cell responses to MEK1/2 inhibitors: Acquired resistance and pathway remodelling

Biochemical Society Transactions

Volumn 40, Issue 1, 2012, Pages 73-78

  Little, Annette S ^a   Balmanno, Kathryn ^a   Sale, Matthew J ^a   Smith, Paul D ^b   Cook, Simon J ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Acquired resistance; B Raf; Extracellular signal regulated kinase 1 2 (ERK1 2); K Ras; Mitogen activated protein kinase extracellular signal regulated kinase kinase 1 2 (MEK1 2); Selumetinib (AZD6244)

Indexed keywords

B RAF KINASE; CYCLIN D1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; ONCOPROTEIN; SELUMETINIB;

CANCER INHIBITION; CELL PROLIFERATION; DRUG MECHANISM; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; DROSOPHILA PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84863397093     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20110647     Document Type: Review

References (28)

1. Yoon, S. and Seger, R. (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44 (Pubitemid 43108774)
2. Karnoub, A.E. and Weinberg, R.A. (2008) Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531 (Pubitemid 351881844)
3. Balmanno, K. and Cook, S.J. (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16, 368-377
4. Drosten, M., Dhawahir, A., Sum, E.Y., Urosevic, J., Lechuga, C.G., Esteban, L.M., Castellano, E., Guerra, C., Santos, E. and Barbacid, M. (2010) Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091-1104
5. Meloche, S. and Pouysségur, J. (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239 (Pubitemid 46763017)
6. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
7. Montagut, C. and Settleman, J. (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283, 125-134
8. Weinstein, I.B. and Joe, A. (2008) Oncogene addiction. Cancer Res. 68, 3077-3080
9. Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516
10. Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J.S., Springer, C.J., Pritchard, C. and Marais, R. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221
11. Downward, J. (2011) Targeting RAF: trials and tribulations. Nat. Med. 17, 286-288
12. Little, A.S., Balmanno, K., Sale, M.J., Newman, S., Dry, J.R., Hampson, M., Edwards, P.A., Smith, P.D. and Cook, S.J. (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signaling 4, ra17
13. Balmanno, K., Chell, S.D., Gillings, A.S., Hayat, S. and Cook, S.J. (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer 125, 2332-2341
14. Solit, D.B., Garraway, L.A., Pratilas, C.A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J.M., She, Y., Osman, I. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (Pubitemid 43128863)
15. Corcoran, R.B., Dias-Santagata, D., Bergethon, K., Iafrate, A.J., Settleman, J. and Engelman, J.A. (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signaling 3, ra84
16. Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J.D., Chresta, C.M., Smith, P.D., Fang, B. and Roth, J.A. (2009) High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol. Ther. 8, 2073-2080
17. Wang, Y., Van Becelaere, K., Jiang, P., Przybranowski, S., Omer, C. and Sebolt-Leopold, J. (2005) A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7, 336-347 (Pubitemid 40664223)
18. Schwab, M. (1998) Amplification of oncogenes in human cancer cells. BioEssays 20, 473-479
19. Delaney, A.M., Printen, J.A., Chen, H., Fauman, E.B. and Dudley, D.T. (2002) Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol. 22, 7593-7602
20. Ohren, J.F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197
21. Ritt, D.A., Monson, D.M., Specht, S.I. and Morrison, D.K. (2010) Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806-819
22. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B. and Rosen, N. (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. U.S.A. 106, 4519-4524
23. Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E. and McMahon, M. (1997) Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5598-5611 (Pubitemid 27357656)
24. Zhu, J., Woods, D., McMahon, M. and Bishop, J.M. (1998) Senescence of human fibroblasts induced by oncogenic Raf. (1998) Genes Dev. 12, 2997-3007 (Pubitemid 28469302)
25. Elgendy, M., Sheridan, C., Brumatti, G. and Martin, S.J. (2011) Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol. Cell 42, 23-35
26. Sharma, S.V., Lee, D.Y., Li, B., Quinlan, M.P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M.A. et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80
27. Engelman, J.A. and Settleman, J. (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73-79 (Pubitemid 351694445)
28. Emery, C.M., Vijayendran, K.G., Zipser, M.C., Sawyer, A.M., Niu, L., Kim, J.J., Hatton, C., Chopra, R., Oberholzer, P.A., Karpova, M.B. et al. (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 20411-20416